Mindset Pharma Inc. (MSSTF)
| Previous Close | 0.2773 |
| Open | 0.2534 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.2452 - 0.2573 |
| 52 Week Range | 0.2398 - 0.8416 |
| Volume | |
| Avg. Volume | 23,151 |
| Market Cap | 23.186M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
TORONTO, June 22, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the Company has entered into an innovative research collaboration with the Centre for Addiction and Mental Health (“CAMH”), a top psychiatric research
- GlobeNewswire
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
TORONTO, June 10, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Mindset’s patent application number 17/387,845, titled, “
- GlobeNewswire
Mindset Pharma to Participate in Upcoming Conferences in June 2022
TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that management will participate in three upcoming conferences: Grizzle Psychedelics Con 2022 to be held virtually on Wednesday, June 8, 2022. James Lanthi
